Meet
Brian Leinwand

Brian Leinwand provides strategic health economics support throughout a product’s life-cycle and helps clients build evidence packages that demonstrate and support the value of their products.

Brian’s area of specialization is economic modeling, and he has developed models to determine the cost-effectiveness and budget impact of medications and medical devices in a range of therapeutic classes. Brian also supports HEOR focused market access activities, such as conducting evidentiary landscape and gap assessments, as well as mapping out and executing on evidence generation strategies to support and strengthen products' value propositions.

Additionally, Brian supports clients in advance of, during, and following formal external third-party value assessments to: 1) provide quantitative support in developing or validating comparative effectiveness and cost-effectiveness analyses; and 2) develop strategies aimed at accurately characterizing and articulating their products’ value and optimally positioning them in the healthcare marketplace.

Prior to joining Avalere, Brian served as a research assistant, at both the University of North Carolina at Chapel Hill and GlaxoSmithKline, and as a health services researcher at Community Care of North Carolina.

Brian has PhD in pharmaceutical outcomes and policy, an MPH in health policy and management, and a BA in management and society from the University of North Carolina at Chapel Hill.

Authored Content


Tune into another episode of Avalere Health Essential Voice in our Start Your Day with Avalere series. In the final segment of our series on infusing the patient perspective into value assessment, our experts discuss the Patient Perspective Value Framework (PPVF) developed by Avalere Health and FasterCures, which employs a form of multi-criteria decision analysis to capture value according to patients.

Join Avalere’s panel of data analytics, market access, and policy experts for a discussion on the potential for federal drug pricing reform in Congress or via administrative action.

Tune into another episode of Avalere Health Essential Voice in our Start Your Day with Avalere series. In this segment, we continue our series on infusing the patient perspective into value assessment with a discussion on the need for a solution to incorporating value drivers outside of traditional endpoints, and introduce a proposed approach to quantify those elements of healthcare value.

Tune into another episode of Avalere Health Essential Voice in our Start Your Day with Avalere series. In this segment, our experts kick off a three-part series about patient perspective in value assessment with an overview of value assessments and value frameworks.

On June 9, Avalere experts discussed new data analytics and approaches for evaluating value-based topics in healthcare in the “New Data Approaches for Novel Curative Therapies & APMs” webinar. They examined the current approaches to assessing the value of treatments, novel curative therapy affordability and access, and the role of data in healthcare decision-making.

Avalere experts discussed new data analytics and health economics and outcomes research approaches for evaluating key value-based topics in healthcare, including novel curative therapy affordability and access, alternative payment models, and the increasingly important role of real-world evidence in healthcare decision-making.

ICER’s reliance on the average number of FDA drug approvals to calculate budget impact thresholds leads to significant variability.

Today, Avalere published a technical appendix to the PPVF Version 1.0 methodology report, outlining a quantitative method for incorporating patient preferences into value assessments and healthcare decision making.